💊 CAR-T & MICROBIOME
📜 Antibiotic Use, Microbiome, and Cell Therapy Outcomes (Blood Advances, 2025) https://lnkd.in/dN9Kjuii
Broad-spectrum antibiotics significantly disrupt the gut microbiome, reducing microbial diversity and depleting key taxa linked to immune homeostasis.
Such microbiome disruption is associated with poor outcomes after cellular therapies, including heightened infection risk and impaired immune reconstitution.
NOVELTY: Emphasises that a careful antibiotic use and microbiome preservation could improve CAR-T therapy safety and effectiveness.
📜Microbiome-Mediated Modulation of CD8+ T Cell-Mediated Anti-Tumor Immunity (Cell, 2025). https://lnkd.in/d5-Q-qXq
Specific gut-derived microbial metabolites such as formate enhance CD8+ T cell function in the tumor microenvironment.
Microbiome composition influences response to cancer immunotherapy, suggesting gut microbes play a role in systemic immune modulation.
NOVELTY: Identifies a mechanistic link between microbial metabolites and T cell–mediated anti-tumor immunity, offering a new avenue for enhancing cancer immunotherapy through microbiome-targeted strategies.
Ketogenic Diet Enhances CAR-T Function via β-Hydroxybutyrate (ASH 2024 Plenary session). https://lnkd.in/duXSiqZf
Ketogenic diet increases β-hydroxybutyrate, improving CAR-T cell metabolism and tumor control.
Higher β-hydroxybutyrate levels in patients correlate with better CAR-T expansion.
NOVELTY: Suggests dietary/metabolic strategies to enhance CAR-T therapy efficacy.
SUMMARY AND IMPLICATIONS 
These findings emphasize the microbiome as a crucial contributor to the success of cellular cancer therapies.
Microbiome profiles could help predict which patients are most likely to respond well to cellular therapies.
Strategies aimed at protecting or restoring a healthy microbiome—such as avoiding unnecessary antibiotics or using microbiome-based treatments—might improve treatment outcomes.
